Capitalizing on emerging insights into cuproptosis-mediated oncotherapy, we have developed a receptor-associated protein (RAP)-modified liposomal nanoplatform (RAP-LPs@ESCu) for the precise delivery of elesclomol-copper complexes (ESCu) and aimed to evaluate its therapeutic potential in triggering tumor-specific cuproptosis. This evidence concerns the gene LRPAP1 and neoplasm.